抗血管生成药物作为晚期上皮卵巢癌的维持策略

 

Article Outline

• Abstract
• 1. Introduction
  • 1.1. Bevacizumab in ovarian cancer
  • 1.2. Novel antiangiogenic agents in gynecologic malignancies
    • 1.2.1. Nintedanib
    • 1.2.2. Sorafenib
    • 1.2.3. Pazopanib
    • 1.2.4. Cediranib
    • 1.2.5. AMG 386
  • 1.3. Current controversies surrounding antiangiogenic maintenance therapy for ovarian cancer
• 2. Conclusion
• Conflict of interest statement
• Role of the funding source
• Reviewers
• Acknowledgements
• References
• Biography
• Copyright

Abstract 

Bevacizumab is the first antiang